RxDoctor Payments Data

Hamid Qazi, MD

Family Medicine · San Marcos, CANPI 1619473162

Payments from drug & device makers

$2,996in general payments, 2019–2025

Across 148 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$416
  • AbbVie$406
  • Johnson & Johnson$240
  • Sanofi$188
  • Novartis$186
  • Incyte Corporation$185
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,81694%
  • Education$1806%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,996 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$32,826
Medicare patients
84
Services billed
618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban23$29,802
OzempicSemaglutide15$17,764
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$7,046
Arnuity ElliptaFluticasone Furoate14$3,616
Atorvastatin Calcium172$1,747
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,419
Losartan Potassium129$1,410
Rosuvastatin Calcium59$1,365
Albuterol Sulfate HfaAlbuterol Sulfate51$1,342
Levothyroxine Sodium117$1,253
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen30$1,180
Gabapentin48$1,049
Tamsulosin Hcl93$1,049
Omeprazole53$969
Amlodipine Besylate126$949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$53$29,80223 claims
Novo NordiskOzempic$171$17,76415 claims
GSKArnuity Ellipta$158$3,61614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in San Marcos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →